Arcutis Biotherapeutics
ARQT
272 hedge funds and large institutions have $3.45B invested in Arcutis Biotherapeutics in 2026 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 95 increasing their positions, 100 reducing their positions, and 36 closing their positions.
999% more call options, than puts
Call options by funds: $17M | Put options by funds: $1.55M
17% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 36
11% more capital invested
Capital invested by funds: $3.12B → $3.45B (+$328M)
1% more funds holding
Funds holding: 270 → 272 (+2)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
5% less repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 100
1.64% less ownership
Funds ownership: 106.72% → 105.08% (-1.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$47.6M |
| 2 |
D.E. Shaw & Co
New York
|
+$33.9M |
| 3 |
BlackRock
New York
|
+$31.3M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$26.7M |
| 5 |
JHC
Jones Hill Capital
New York
|
+$25.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$69.7M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$46.2M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$31.4M |
| 4 |
Jennison Associates
New York
|
-$17.7M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$17.3M |
ARQT Hedge Fund Activity: Q2 2026 in Review
272 of the 8,303 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q2 2026, worth a combined $3.45B — up 11% from $3.12B a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new ARQT positions and 36 closed out — a net gain of 6 holders — while 95 added to existing stakes and 100 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $47.6M. The largest seller was Gilder Gagnon Howe & Co, cutting an estimated $69.7M.
- 272 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q2 2026, up from 270 in Q1 2026.
- Funds reported $3.45B of Arcutis Biotherapeutics stock for Q2 2026, up 11% quarter-over-quarter.
- 42 funds opened new Arcutis Biotherapeutics positions in Q2 2026 and 36 closed out, a net change of +6 holders.
- The largest Arcutis Biotherapeutics buyer in Q2 2026 was OrbiMed, an estimated $47.6M added.
- The largest Arcutis Biotherapeutics seller in Q2 2026 was Gilder Gagnon Howe & Co, an estimated $69.7M sold.
Based on aggregated 13F filings for Q2 2026.